Merger communication
Open the filing on sec.gov
Drugs Made In America Acquisition Corp. (DMAA)
Nasdaq: DMAA · Blank Checks · filing with the SEC since 2024
The companyfiscal 2025, as filed
Revenuen/a
Net income$5.9M
Earnings per sharen/a
Operating cash flow-$539,187
Cash$6137.00+354.3%
Debtn/a
Shareholders’ equity-$7.3M-2866.8%
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202627
Newest filingOct 21 · 425
Annual reportApr 15, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 monthsn/a
Insider buys, 12 monthsn/a
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income $6.1MCash from operations -$517,145the four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.